Nothing Special   »   [go: up one dir, main page]

HRP20050534A2 - Prevention and treatment of alzheimer's disease - Google Patents

Prevention and treatment of alzheimer's disease

Info

Publication number
HRP20050534A2
HRP20050534A2 HR20050534A HRP20050534A HRP20050534A2 HR P20050534 A2 HRP20050534 A2 HR P20050534A2 HR 20050534 A HR20050534 A HR 20050534A HR P20050534 A HRP20050534 A HR P20050534A HR P20050534 A2 HRP20050534 A2 HR P20050534A2
Authority
HR
Croatia
Prior art keywords
inhibitor
alzheimer
disease
prevention
treatment
Prior art date
Application number
HR20050534A
Other languages
Croatian (hr)
Inventor
Canton Thierry
Pradier Laurent
Benavides J�sus
Heuer Hubert
Schaefer Hans-Ludwig
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of HRP20050534A2 publication Critical patent/HRP20050534A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Abstract

Prikazani izum se odnosi na primjenu inhibitora intestinalnog apsorpcije bilijarnih kiselina u prevenciji i liječenju Alzheimerove bolesti, po izboruu kombinaciji sa inhibitorom HMG-CoA reduktaze, inhibitorom apsorpcije kolesterola, inhibitorom sinteze kolesterola ili inhibitorom APP sekretaze.The present invention relates to the use of an inhibitor of intestinal biliary acid absorption in the prevention and treatment of Alzheimer's disease, optionally in combination with an HMG-CoA reductase inhibitor, a cholesterol absorption inhibitor, a cholesterol synthesis inhibitor or an APP secretase inhibitor.

HR20050534A 2002-12-12 2005-06-10 Prevention and treatment of alzheimer's disease HRP20050534A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0215722A FR2848452B1 (en) 2002-12-12 2002-12-12 APPLICATION OF INTESTINAL BILIARY ACID RECAPTURE INHIBITORS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE
PCT/FR2003/003654 WO2004062652A1 (en) 2002-12-12 2003-12-10 Prevention and treatment of alzheimer's disease

Publications (1)

Publication Number Publication Date
HRP20050534A2 true HRP20050534A2 (en) 2006-11-30

Family

ID=32338722

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050534A HRP20050534A2 (en) 2002-12-12 2005-06-10 Prevention and treatment of alzheimer's disease

Country Status (22)

Country Link
EP (1) EP1572174A1 (en)
JP (1) JP2006514063A (en)
KR (1) KR20050084250A (en)
CN (1) CN1726016A (en)
AR (1) AR042354A1 (en)
AU (1) AU2003296802A1 (en)
BR (1) BR0317280A (en)
CA (1) CA2507945A1 (en)
CO (1) CO5700712A2 (en)
FR (1) FR2848452B1 (en)
HR (1) HRP20050534A2 (en)
MA (1) MA27500A1 (en)
MX (1) MXPA05005556A (en)
NO (1) NO20053341L (en)
NZ (1) NZ540496A (en)
PE (1) PE20040770A1 (en)
PL (1) PL377110A1 (en)
RS (1) RS20050420A (en)
RU (1) RU2005121909A (en)
TW (1) TW200503707A (en)
WO (1) WO2004062652A1 (en)
ZA (1) ZA200504656B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
NZ546887A (en) 2003-11-03 2009-04-30 Probiodrug Ag Combinations useful for the treatment of neuronal disorders
EP1713780B1 (en) 2004-02-05 2012-01-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
US8158627B2 (en) 2006-04-28 2012-04-17 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
AR066664A1 (en) * 2007-05-22 2009-09-02 Otsuka Pharma Co Ltd A MEDICINAL PRODUCT TO TREAT ALZHEIMER'S DISEASE
BR112014010228B1 (en) * 2011-10-28 2020-09-29 Lumena Pharmaceuticals Llc USE OF BILIARY ACID RECYCLING INHIBITORS FOR THE TREATMENT OF HYPERCOLEMIA AND CHOLESTATIC HEPATIC DISEASE
EA201891154A1 (en) 2011-10-28 2019-02-28 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи INHIBITORS OF BILIC ACID RECYCLING IN THE TREATMENT OF CHOLESTATIC DISEASES OF THE LIVER IN CHILDREN

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2040996A1 (en) * 1990-05-02 1991-11-03 Robert L. Albright Composition and method for controlling cholesterol
CA2104594C (en) * 1991-02-22 2004-05-11 Howard K. Shapiro Use of pharmaceutical compounds in the treatment of symptoms of disorders related to neurological diseases and etiologically related symptomology
US6383500B1 (en) * 1996-06-27 2002-05-07 Washington University Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications
US5985936A (en) * 1997-12-18 1999-11-16 Forbes Medi-Tech, Inc. Method of preventing and delaying onset of Alzheimer's disease and composition therefor
ES2257824T3 (en) * 1998-01-28 2006-08-01 Warner-Lambert Company Llc METHOD TO TREAT ALZHEIMER'S DISEASE.
US6080778A (en) * 1998-03-23 2000-06-27 Children's Medical Center Corporation Methods for decreasing beta amyloid protein
US6221897B1 (en) * 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19825804C2 (en) * 1998-06-10 2000-08-24 Aventis Pharma Gmbh 1,4-Benzothiepin-1,1-dioxide derivatives, processes for their preparation and medicaments containing these compounds
DE19845405C2 (en) * 1998-10-02 2000-07-13 Aventis Pharma Gmbh Aryl-substituted propanolamine derivatives and their use
US20010028895A1 (en) * 2000-02-04 2001-10-11 Bisgaier Charles L. Methods of treating alzheimer's disease
US20020028826A1 (en) * 2000-06-15 2002-03-07 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
SE0104334D0 (en) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
TWI329111B (en) * 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
NO20053341L (en) 2005-09-07
KR20050084250A (en) 2005-08-26
MXPA05005556A (en) 2005-07-26
PL377110A1 (en) 2006-01-23
AU2003296802A1 (en) 2004-08-10
RU2005121909A (en) 2006-01-20
CN1726016A (en) 2006-01-25
WO2004062652A1 (en) 2004-07-29
RS20050420A (en) 2007-04-10
ZA200504656B (en) 2006-08-30
NO20053341D0 (en) 2005-07-08
JP2006514063A (en) 2006-04-27
FR2848452B1 (en) 2007-04-06
FR2848452A1 (en) 2004-06-18
TW200503707A (en) 2005-02-01
NZ540496A (en) 2008-04-30
CO5700712A2 (en) 2006-11-30
BR0317280A (en) 2005-11-08
CA2507945A1 (en) 2004-07-29
PE20040770A1 (en) 2004-12-10
AR042354A1 (en) 2005-06-15
MA27500A1 (en) 2005-08-01
EP1572174A1 (en) 2005-09-14

Similar Documents

Publication Publication Date Title
ATE299890T1 (en) INHIBITORS OF GAMMA SECRETASE
BR9914044A (en) tetrahydropyride esters
TNSN01125A1 (en) PHARMACEUTICAL COMPOSITIONS COMPRISING A CETP AND ATORVASTATIN INHIBITOR
DE60312017D1 (en) SULPHONE DERIVATIVES FOR INHIBITING GAMMA SECRETASE
ECSP045429A (en) COMBINATION OF ORGANIC COMPOUNDS
ATE443043T1 (en) PHENYLCARBOXAMIDE AS A BETA-SECRETASE INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S
ATE464287T1 (en) CYCLOHEXYL SULPHONES AS GAMMA SECRETASE INHIBITORS
ATE346039T1 (en) SULFONAMIDO-SUBSTITUTED BRIDGED BICYCLOALKYL DERIVATIVES
PA8577901A1 (en) PHARMACEUTICAL FORMULATION
ATE416761T1 (en) PREVENTION AND TREATMENT OF INFLAMMATORY AND/OR IMMUNE-MEDIATED BONE LOSS
DE60237725D1 (en) DEVICE OF DEXRAZOXANE IN THE PREVENTION AND TREATMENT OF ALZHEIMER DISEASE
BRPI0312331A2 (en) hyaluronic acid compositions and methods of use.
DE60134874D1 (en) BENZODIAZEPINE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS
EE05556B1 (en) Use of 3-hydroxy-3-methylglutaryl coenzyme as a reductase inhibitor in the preparation of a medicament for the treatment of diabetic neuropathy
PT1115701E (en) ARILSULFONANILIDA UREES
NO20074941L (en) Use of diosmetine compounds in the treatment and prevention of thrombotic pathologies
MXPA04000793A (en) Use of a pde4 inhibitor in combination with an anticholinergic agent for the treatment of pulmonary disease such as asthma.
PA8583601A1 (en) PIRROLIDONE DERIVATIVES AS MAOB INHIBITORS
PT1560812E (en) AMINOCYCLOHEXYL ETER COMPOUNDS AND THEIR USES
ATE482936T1 (en) 2-AMINO-QUINAZOLINE DERIVATIVES USEFUL AS B-SECRETASE (BACE) INHIBITORS
AU2003231252A1 (en) Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
MXPA05009986A (en) Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders.
WO2003106450A8 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
NO20076405L (en) Use of 24-nor-UDCA
HRP20050534A2 (en) Prevention and treatment of alzheimer's disease

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20071207

Year of fee payment: 5

OBST Application withdrawn